Appendix 3

Examples of Insulin Initiation and Titration Regimens in People with Type 2 Diabetes

All people starting insulin should be counseled about the recognition, prevention and treatment of hypoglycemia. Consider a change in type or timing of insulin administration if glycemic targets are not being reached.
 
Example A: Basal insulin (Humulin®-N, Lantus®, Levemir®, Novolin®ge NPH) added to oral antihyperglycemic agents
• Insulin should be titrated to achieve target fasting BG levels of 4.0 to 7.0 mmol/L.
• Individuals can be taught self-titration, or titration may be done in conjunction with a healthcare provider.
• Suggested starting dose is 10 units once daily at bedtime.
• Suggested titration is 1 unit per day until target is reached.
• A lower starting dose, slower titration and higher targets may be considered for elderly or normal weight subjects.
• In order to safely titrate insulin, patients must perform SMBG at least once a day fasting.
• Insulin dose should not be increased if the individual experiences 2 episodes of hypoglycemia (BG <4.0 mmol/L) in 1 week or any episode of nocturnal hypoglycemia.
• For fasting BG levels consistently <5.5 mmol/L, a reduction of 1 to 2 units of insulin may be considered to avoid nocturnal hypoglycemia.
• Oral antihyperglycemic agents (especially secretagogues) may need to be reduced if daytime hypoglycemia occurs.
 
Example B: Basal Plus Strategy - Adding bolus (prandial) insulin (Apidra®, Humalog®, NovoRapid®) once daily to optimized basal insulin therapy
• When intensification of insulin therapy is necessary, start one injection of meal time insulin to either main meal or breakfast.
• Starting dose is 2 to 4 units and patient can be taught self titration or dose increase can be done by HCP.
• To safely increase dose, glucose levels should be measured at least prior to insulin dose then titrated by 1 unit daily to either of the following targets.
  – 2 hour post meal glucose of 10.0 mmol/L (or ≤ 8.0 mmol/L in certain cases)
  – pre-meal glucose of the next meal of 4.0 to 7.0 mmol/L.
• Important to keep carbohydrate intake constant. Oral antihyperglycemic agents (especially secretegogues) may need to be reduced or stopped particularly if daytime hypoglycemia occurs.
 
Example C: Basal-Bolus Insulin - Intensive insulin therapy
• Calculate total daily dose of 0.3 to 0.5 units/kg then distribute as follows:
  a. 40% of total insulin dose as basal insulin (Humulin®-N, Lantus®, Levemir®, Novolin®ge NPH).
  b. 20% of total insulin as bolus (prandial) insulin 3 times per day using either rapid-acting insulin analogue (Apidra®, Humalog®, NovoRapid®) or short-acting insulin (Humulin®, Novolin®ge Toronto).
 
Example D: Premixed insulin (Humulin® 30/70, Novolin® 30/70, Humalog® Mix 25 or Humalog® Mix 50, NovoMix® 30,) added to oral antihyperglycemic agents
• Suggested starting dose is 5 to 10 units once or twice daily (prebreakfast and/or presupper).
• Suggested titration is 1 to 2 units added to prebreakfast dose and/or presupper dose daily until target BG values are reached based on prebreakfast and presupper BG readings.
• Prebreakfast premixed insulin achieves presupper target BG value (4.0 to 7.0 mmol/L).
• Presupper premixed insulin achieves target fasting BG value (4.0 to 7.0 mmol/L).
• 30/70 premixed insulin should be given 30 to 45 minutes before meals.
• Humalog® Mix 25 or NovoMix® 30 premixed insulin should be given immediately before eating.
• Stop increasing insulin when both target BG levels are reached.
• If both BG targets are not reached, continue to increase the relevant dose until both targets achieved.
• The individual needs to self-monitor BG at least twice daily to safely titrate insulin.
• Insulin dose should not be increased if the individual experiences 2 or more episodes of hypoglycemia (BG <4.0 mmol/L) in 1 week or any episode of nocturnal hypoglycemia.
• Oral antihyperglycemic agents (especially secretagogues) may need to be reduced or stopped at the start of this regimen or when daytime hypoglycemia occurs.

Click to view printable and saveable pdf


*The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. All content on guidelines.diabetes.ca, CPG Apps and in our online store remains exactly the same. For questions, contact communication@diabetes.ca.